These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 14694058)

  • 1. Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab.
    Rojas-García R; Gallardo E; de Andrés I; de Luna N; Juarez C; Sánchez P; Illa I
    Neurology; 2003 Dec; 61(12):1814-6. PubMed ID: 14694058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic ataxic neuropathy with cold agglutinins: atypical phenotype and response to anti-CD20 antibodies.
    Siddiqui K; Cahalane E; Keogan M; Hardiman O
    Neurology; 2003 Nov; 61(9):1307-8. PubMed ID: 14610153
    [No Abstract]   [Full Text] [Related]  

  • 3. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab.
    Levine TD; Pestronk A
    Neurology; 1999 May; 52(8):1701-4. PubMed ID: 10331706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic ataxic neuropathy mimicking dorsal midbrain syndrome.
    Arbogast SD; Khanna S; Koontz DW; Tomsak RL; Katirji B; Leigh RJ
    J Neurol Neurosurg Psychiatry; 2007 Nov; 78(11):1276-7. PubMed ID: 17504882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Measurement of antiganglioside autoantibodies by immunodot-blot assay: clinical importance in peripheral neuropathies].
    Caudie C; Vial C; Petiot P; Bancel J; Later R; Gonnaud PM
    Ann Biol Clin (Paris); 1999; 57(5):579-88. PubMed ID: 10518060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease.
    Berentsen S; Tjønnfjord GE; Brudevold R; Gjertsen BT; Langholm R; Løkkevik E; Sørbø JH; Ulvestad E
    Br J Haematol; 2001 Oct; 115(1):79-83. PubMed ID: 11722415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity.
    Maurer MA; Rakocevic G; Leung CS; Quast I; Lukačišin M; Goebels N; Münz C; Wardemann H; Dalakas M; Lünemann JD
    J Clin Invest; 2012 Apr; 122(4):1393-402. PubMed ID: 22426210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Identification and characterization of a monoclonal IgM reacting with disialylated gangliosides recognizing the CANOMAD syndrome].
    Boussaïd I; Bouhour F; Vial C; Caudie C
    Ann Biol Clin (Paris); 2011; 69(4):476-80. PubMed ID: 21896416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
    Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
    Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab therapy in monoclonal IgM-related neuropathies.
    Kilidireas C; Anagnostopoulos A; Karandreas N; Mouselimi L; Dimopoulos MA
    Leuk Lymphoma; 2006 May; 47(5):859-64. PubMed ID: 16753870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Worsening after rituximab treatment in anti-mag neuropathy.
    Broglio L; Lauria G
    Muscle Nerve; 2005 Sep; 32(3):378-9. PubMed ID: 15986418
    [No Abstract]   [Full Text] [Related]  

  • 12. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg.
    Rüegg SJ; Fuhr P; Steck AJ
    Neurology; 2004 Dec; 63(11):2178-9. PubMed ID: 15596777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-ganglioside complex IgM antibodies in multifocal motor neuropathy and chronic immune-mediated neuropathies.
    Nobile-Orazio E; Giannotta C; Briani C
    J Neuroimmunol; 2010 Feb; 219(1-2):119-22. PubMed ID: 20006388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of IgM antibody associated polyneuropathies using rituximab.
    Pestronk A; Florence J; Miller T; Choksi R; Al-Lozi MT; Levine TD
    J Neurol Neurosurg Psychiatry; 2003 Apr; 74(4):485-9. PubMed ID: 12640069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, specificity and functionality of anti-ganglioside antibodies in neuropathy associated with IgM monoclonal gammopathy.
    Stork AC; Jacobs BC; Tio-Gillen AP; Eurelings M; Jansen MD; van den Berg LH; Notermans NC; van der Pol WL
    J Neuroimmunol; 2014 Mar; 268(1-2):89-94. PubMed ID: 24529728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy.
    Zara G; Zambello R; Ermani M
    Clin Neurophysiol; 2011 Dec; 122(12):2518-22. PubMed ID: 21680240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cranial nerve palsies: ganglioside autoantibodies indicating an immunoneuropathy].
    Banati M; Vachalova I; Vynogradova I; Heckmann JG
    Dtsch Med Wochenschr; 2015 Jul; 140(15):1154-7. PubMed ID: 26230068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiganglioside autoantibody profiles in Guillain-Barré syndrome].
    Caudie C; Vial C; Bancel J; Petiot P; Antoine JC; Gonnaud PM
    Ann Biol Clin (Paris); 2002; 60(5):589-97. PubMed ID: 12368145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rituximab and autoimmune disorders therapy].
    Quint L
    Rev Med Interne; 2004 Oct; 25(10):752-4. PubMed ID: 15471601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal IgM autoantibody reactivity in M-IgM peripheral neuropathy.
    Caudie C
    Clin Rev Allergy Immunol; 2000 Aug; 19(1):7-18. PubMed ID: 11064822
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.